Shenzhen Hybio Pharmaceutical (revision 14)
Old revision·10:43, 2 Nov 2025·Chromatokid
| Shenzhen Hybio Pharmaceutical Co., Ltd.Organisation | |
|---|---|
Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki. | |
| Legal name | Shenzhen Hybio Pharmaceutical Co., Ltd. |
| Trading name | HYB |
| Other designations | Hybio, Hybio Pharmaceutical, 深圳翰宇药业股份有限公司 |
| Identity | |
| Founded | 2003 |
| Headquarters | Shenzhen, Guangdong, China |
| Industry | Research-compound supply |
| Official site | Visit HYB at hybiopharmaceutical.com |
| Products and documentation | |
| Product scope | peptide active pharmaceutical ingredients, contract manufacturing, research peptides and raw materials |
| Catalogue size | 350+ listings (self-reported) |
| Documentation | Batch certificate of analysis reported with orders |
| Independent reports | Submitted to this wiki by purchasers; see §Independent testing record |
| Organisation infobox · conventions | |
Shenzhen Hybio Pharmaceutical Co., Ltd. (trading as HYB; hybiopharmaceutical.com) is a peptide active-ingredient manufacturer and contract development organisation trading as HYB from Shenzhen, Guangdong, China, incorporated in 2003 and supplying research peptides and raw materials with batch documentation.[1][2]
The organisation is one of twenty-two covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.[3]
This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.[4]
Corporate identity and history
[edit]Incorporated in Shenzhen in 2003, the organisation sits with the earlier incorporation dates among the entities covered on this wiki and predates the current research-peptide market by roughly a decade.[1] Shenzhen is inside the Pearl River Delta manufacturing belt, and the organisation's own material describes a business built on peptide active pharmaceutical ingredient supply and contract development rather than on catalogue distribution alone.[2]
The organisation describes itself as operating as a contract development and manufacturing organisation alongside its own listings. That is a self-published characterisation and is recorded here as one: nothing available to this wiki establishes the manufacturing arrangements behind it, and a registered business scope is a licensing fact rather than a capability finding.[2][1]
The documentary base is the registry record, the organisation's own material and purchaser-submitted test reports. No independent coverage has been identified, which is a characteristic of the sector rather than of this entity.
Distribution and dispatch
[edit]The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.
Operations and documentation practice
[edit]Purchaser reports describe vialled lyophilised material arriving with a batch-specific certificate naming a lot, and across the submitted set the lot string on the certificate has corresponded to the vial label.[5] That correspondence is a minimum requirement rather than an achievement, and it is recorded only because traceability fails often enough elsewhere in this sector to make its absence the more common finding.
Water content by Karl Fischer titration appears on the certificates described in the submitted set more often than for most entities covered here, and peptide content is reported on a separate line from chromatographic purity across a substantial part of it.[5][6] Those two determinations are what let a purity percentage be read as a statement about mass, and their routine presence is the most useful documentary observation available about this organisation.
What the record does not establish is the physical arrangement of manufacture, whether synthesis is performed in-house or contracted out, or what quality system governs it. Statements to that effect in the organisation's own material are self-published and are not corroborated here.[2][7]
Product range
[edit]| Class | Representative listings | Documentation reported |
|---|---|---|
| Peptide active ingredients | Bulk peptide actives, protected fragments | Specification sheet with purity, water and content |
| Incretin analogues | Semaglutide, tirzepatide, retatrutide | Batch certificate with HPLC trace and mass confirmation |
| Research peptides | BPC-157, TB-500, growth-hormone secretagogues | Certificate with purity, appearance and water |
| Custom synthesis | Sequences quoted individually | Certificate with mass confirmation and stated analytical conditions |
| Raw materials | Bulk powders | Certificate with purity; specification sheet on request |
The active-ingredient listings are documented differently from the catalogue lines — a specification sheet rather than a single purity figure, and in places a reference to a drug master file said to be held with a regulator elsewhere. Whether such a file exists, and what it covers, is not established by any source available to this wiki, and a reader should treat the reference as a claim until it is.[2]
Independent testing record
[edit]Reports on HYB material submitted to PeptidePedia between 2024 and 2026 cover the incretin analogues most heavily, with a smaller set on repair and secretagogue peptides and a handful on bulk raw material. Reported area percent figures have been high across the set, and where a report and the accompanying certificate can be compared the two have generally agreed within a few tenths of a percentage point.[5]
See also
References
- ^ a b c National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.
- ^ a b c d e Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per Project:Verifiability.
- ^ Research-use-only labelling practice; see Research use only for the legal and commercial function of the phrase.
- ^ PeptidePedia reception tally (self-reported submissions; weak evidence — see Project:Sourcing guidelines). Self-selected sample; period and count stated at each point of use.
- ^ a b c Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See Blind sampling.
- ^ United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.
- ^ World Health Organization, Good Manufacturing Practices for Pharmaceutical Products: Main Principles, WHO Technical Report Series. The general framework against which a GMP claim is assessed.